me,me,me,me........too Eddy!
Stay awake with CEPH along you mean to say?
Cephalon, Inc. engages in the discovery, development, and marketing of products in central nervous system disorders, pain, cancer, and addiction therapeutic areas. It products for central nervous system disorders include PROVIGIL, a dosage form of modafinil for improving wakefulness in patients with excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSA/HS), and shift work sleep disorder (SWSD); and GABITRIL for use as adjunctive therapy in the treatment of partial seizures in epileptic patients. The company’s products also comprise NUVIGIL in Phase 3 clinical trials for patients suffering from excessive sleepiness associated with narcolepsy, SWSD or OSA/HS; and SPARLON that are in the process of receiving final FDA approval. Cephalon has an agreement with Pharmacopeia Drug Discovery for the discovery, development, and commercialization of therapeutic products. It operates in the United States and Europe. The company was founded in 1987 and is headquartered Frazer, Pennsylvania. |
